Hubei Biocause Pharmaceutical Total Assets
Hubei Biocause Pharmaceutical total assets. Based on the latest financial reports, Hubei Biocause Pharmaceutical (000627) holds total assets worth CN¥285.15 Billion CNY (≈ $41.73 Billion USD) as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Hubei Biocause Pharmaceutical market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Hubei Biocause Pharmaceutical (2000–2023)
Total assets of Hubei Biocause Pharmaceutical from 2000 to 2023. This chart illustrates how Hubei Biocause Pharmaceutical's total assets have evolved over time, based on quarterly financial data. See Hubei Biocause Pharmaceutical share price for real-time trading data and today's change.
Hubei Biocause Pharmaceutical - Asset Composition Analysis
Hubei Biocause Pharmaceutical Total Assets Breakdown (December 2023)
Hubei Biocause Pharmaceutical total assets breakdown as of December 2023. Hubei Biocause Pharmaceutical's total assets of CN¥285.15 Billion consist of 16.8% current assets and 83.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 9.3% |
| Accounts Receivable | CN¥77.20 Million | 0.0% |
| Inventory | CN¥4.13 Billion | 1.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥283.20 Million | 0.1% |
| Goodwill | CN¥6.19 Billion | 2.1% |
Asset Composition Trend (2000–2023)
This chart illustrates how Hubei Biocause Pharmaceutical's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Hubei Biocause Pharmaceutical short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hubei Biocause Pharmaceutical's current assets represent 16.8% of total assets in 2023, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 9.3% of total assets in 2023, down from 11.8% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 11.0% in 2000.
- Asset Diversification: The largest asset category is goodwill at 2.1% of total assets.
Hubei Biocause Pharmaceutical Competitors by Total Assets
Key competitors of Hubei Biocause Pharmaceutical based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
HDFC Life Insurance Company Limited
NSE:HDFCLIFE
|
India | Rs4.14 Trillion |
|
Max Financial Services Limited
NSE:MFSL
|
India | Rs1.99 Trillion |
|
Challenger Ltd
AU:CGF
|
Australia | AU$35.37 Billion |
|
Clearview Wealth Ltd
AU:CVW
|
Australia | AU$1.07 Billion |
|
Nobleoak Life Ltd
AU:NOL
|
Australia | AU$600.63 Million |
|
Manulife Financial Corp
TO:MFC
|
Canada | CA$1.09 Trillion |
|
Great-West Lifeco Inc.
TO:GWO
|
Canada | CA$862.83 Billion |
|
Power Corporation Of Canada
TO:POW
|
Canada | CA$1.02 Trillion |
Hubei Biocause Pharmaceutical - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.02 | 2.08 | 3.06 |
| Quick Ratio | 1.80 | 1.91 | 2.62 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥17.75 Billion | CN¥24.66 Billion | CN¥17.35 Billion |
Hubei Biocause Pharmaceutical - Advanced Valuation Insights
This section examines the relationship between Hubei Biocause Pharmaceutical's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.36 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 4.6% |
| Total Assets | CN¥301.94 Billion |
| Market Capitalization | $1.13 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hubei Biocause Pharmaceutical's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hubei Biocause Pharmaceutical's assets grew by 4.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hubei Biocause Pharmaceutical (2000–2023)
The table below shows the annual total assets of Hubei Biocause Pharmaceutical from 2000 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | CN¥301.94 Billion ≈ $44.18 Billion |
+4.62% |
| 2022-12-31 | CN¥288.60 Billion ≈ $42.23 Billion |
+9.36% |
| 2021-12-31 | CN¥263.90 Billion ≈ $38.62 Billion |
+10.23% |
| 2020-12-31 | CN¥239.40 Billion ≈ $35.03 Billion |
+16.63% |
| 2019-12-31 | CN¥205.27 Billion ≈ $30.04 Billion |
+15.16% |
| 2018-12-31 | CN¥178.25 Billion ≈ $26.08 Billion |
+26.95% |
| 2017-12-31 | CN¥140.42 Billion ≈ $20.55 Billion |
+19.12% |
| 2016-12-31 | CN¥117.88 Billion ≈ $17.25 Billion |
+4792.75% |
| 2015-12-31 | CN¥2.41 Billion ≈ $352.54 Million |
+14.26% |
| 2014-12-31 | CN¥2.11 Billion ≈ $308.54 Million |
-2.25% |
| 2013-12-31 | CN¥2.16 Billion ≈ $315.63 Million |
+4.47% |
| 2012-12-31 | CN¥2.06 Billion ≈ $302.13 Million |
+9.62% |
| 2011-12-31 | CN¥1.88 Billion ≈ $275.63 Million |
-4.69% |
| 2010-12-31 | CN¥1.98 Billion ≈ $289.20 Million |
-8.32% |
| 2009-12-31 | CN¥2.16 Billion ≈ $315.45 Million |
+8.90% |
| 2008-12-31 | CN¥1.98 Billion ≈ $289.67 Million |
+49.45% |
| 2007-12-31 | CN¥1.32 Billion ≈ $193.82 Million |
+13.46% |
| 2006-12-31 | CN¥1.17 Billion ≈ $170.82 Million |
+7.30% |
| 2005-12-31 | CN¥1.09 Billion ≈ $159.20 Million |
+0.61% |
| 2004-12-31 | CN¥1.08 Billion ≈ $158.23 Million |
-0.88% |
| 2003-12-31 | CN¥1.09 Billion ≈ $159.64 Million |
+0.05% |
| 2002-12-31 | CN¥1.09 Billion ≈ $159.56 Million |
+10.24% |
| 2001-12-31 | CN¥989.09 Million ≈ $144.73 Million |
+11.59% |
| 2000-12-31 | CN¥886.33 Million ≈ $129.70 Million |
-- |
About Hubei Biocause Pharmaceutical
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ethe… Read more